Cargando…

Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019

This economic evaluation examines the magnitude and trend of prescription drug rebates in commercial markets from 2015 to 2019 and identifies insurance plan factors associated with rebates.

Detalles Bibliográficos
Autores principales:	Plummer, Elizabeth, Socal, Mariana P., Ballreich, Jeromie M., Anderson, Gerard F., Bai, Ge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077484/ https://www.ncbi.nlm.nih.gov/pubmed/35977258 http://dx.doi.org/10.1001/jamahealthforum.2022.0888

Ejemplares similares

Branded prescription drug spending: a framework to evaluate policy options
por: Ballreich, Jeromie, et al.
Publicado: (2017)

Association Between Waste-Free Formularies and Prescription Drug Spending Among Self-insured Employers
por: Socal, Mariana P., et al.
Publicado: (2021)

Trajectories of prices in generic drug markets: what can we infer from looking at trajectories rather than average prices?
por: Trujillo, Antonio J., et al.
Publicado: (2022)

Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers
por: Lin, Dora H., et al.
Publicado: (2018)

The Relative Value of Disease Management Programs Versus Drug Manufacturer Rebates
por: Curtiss, Frederic R.
Publicado: (2003)

Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry
por: Padula, William V., et al.
Publicado: (2018)

Argumentación rebatible : modelos y aplicaciones
por: Bodanza, Gustavo Adrián
Publicado: (2011)

Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program
por: Socal, Mariana P., et al.
Publicado: (2021)

Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
por: Hussaini, S. M. Qasim, et al.
Publicado: (2022)

Claim for Rebate of Spirit Duty
por: Churchfield, Jas. M.
Publicado: (1917)

Implications of drugs with rebate in Europe
por: Bonetti, Andrea, et al.
Publicado: (2021)

Physicians’ Rebate Check-Book
Publicado: (1892)

Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019
por: Ballreich, Jeromie M., et al.
Publicado: (2021)

Trends in Testosterone Prescriptions for Older Men Enrolled in Commercial Insurance and Medicare Advantage
por: Everhart, Alexander, et al.
Publicado: (2021)

Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019
por: Clemans-Cope, Lisa, et al.
Publicado: (2023)

Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs
por: Murimi-Worstell, Irene B., et al.
Publicado: (2019)

Trends in Prescriptions for Insomnia in a Province in China Between 2015 and 2019
por: Lou, Guodong, et al.
Publicado: (2022)

Premium Rebates and the Quiet Consensus on Market Reform for Medicare
por: Feldman, Roger, et al.
Publicado: (2001)

Estimating & comparing greenhouse gas emissions for existing intramuscular COVID-19 vaccines and a novel thermostable oral vaccine
por: Patenaude, Bryan, et al.
Publicado: (2022)

Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19
por: Patenaude, Bryan, et al.
Publicado: (2022)

Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults — United States, 2016–2021
por: Danielson, Melissa L., et al.
Publicado: (2023)

Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018
por: Yeung, Kai, et al.
Publicado: (2021)

Trends in Premiums, Claims, and Enrollment for Fully Insured Large Group, Small Group, and Individual Health Plans From 2011 to 2021
por: Plummer, Elizabeth, et al.
Publicado: (2023)

Trends in Disenrollment and Reenrollment Within US Commercial Health Insurance Plans, 2006-2018
por: Fang, Hanming, et al.
Publicado: (2022)

Discounts and rebates granted to public payers for medicines in European countries
por: Vogler, Sabine, et al.
Publicado: (2012)

Paediatric genomic testing: Navigating medicare rebatable genomic testing
por: Sachdev, Rani, et al.
Publicado: (2021)

Patterns of Manufacturer Coupon Use for Prescription Drugs in the US, 2017-2019
por: Kang, So-Yeon, et al.
Publicado: (2023)

Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs
por: Ballreich, Jeromie, et al.
Publicado: (2022)

HIV Testing Trends Among Persons with Commercial Insurance or Medicaid — United States, 2014–2019
por: Henny, Kirk D., et al.
Publicado: (2021)

Consider expenditure controls’ impacts on equity
por: Frick, Kevin D, et al.
Publicado: (2021)

Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV
por: Ballreich, Jeromie, et al.
Publicado: (2022)

Footing the bill: the introduction of Medicare Benefits Schedule rebates for podiatry services in Australia
por: Short, Anthony J
Publicado: (2009)

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates
por: Espin, Jaime, et al.
Publicado: (2018)

Naloxone Prescriptions Among Commercially Insured Individuals at High Risk of Opioid Overdose
por: Follman, Sarah, et al.
Publicado: (2019)

Provider and Patient Characteristics of Medicare Beneficiaries Who Are High-Risk for COVID-19 Mortality
por: Ballreich, Jeromie, et al.
Publicado: (2021)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Patterns and trends of antibacterial treatment in patients with urinary tract infections, 2015–2019: an analysis of health insurance data
por: Schmiemann, Guido, et al.
Publicado: (2022)

Trends and patterns of neurotology drug prescriptions on a nationwide insurance database
por: Goshtasbi, Khodayar, et al.
Publicado: (2021)

Trends in Insurance Coverage for Acupuncture, 2010-2019
por: Candon, Molly, et al.
Publicado: (2022)

Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe
por: Carl, David L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uemlefdf14oumt0luef9v90pja